technologynetworks

Mainz Biomed Announces US Extension of ColoFuture Study To Evaluate Integration of Novel mRNA Biomarkers Into ColoAlert

Mainz Biomed NV (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, has announced the initiation of eAArly DETECT, its US ...
dbta

What to Look for when Evaluation Integration as a Service Solutions

The decisions you make when evaluating “integration as a service” as part of your cloud computing strategy will affect your overall integration strategy well into the future. This whitepaper addresses ...
technologynetworks

Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers Into ColoAlert

Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the first patient has been ...
ascopubs.org

A randomized trial evaluating the integration of online questionnaires into follow-up (FU) care for early-stage breast cancer (ESBC).

Understanding the symptom experience of breast cancer outpatients: The validity and utility of the M.D. Anderson Symptom Inventory (MDASI). This is an ASCO Meeting Abstract from the 2012 ASCO Annual ...
Yahoo Finance

Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert

Potential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to colorectal cancer (CRC) BERKELEY, Calif. and MAINZ, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed ...
Yahoo Finance

Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

Enrollment remains on track to complete in Q1 2023 with results in 1H 2023 Potential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to colorectal cancer (CRC) BERKELEY, ...